Forward looking statements

This presentation contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Statements in this presentation which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. These forward-looking statements generally can be identified by phrases such as Q BioMed, Inc. (“QBIO”) or its management "believes," "expects," "anticipates," "foresees," “forecasts,” “estimates” or other words or phrases of similar importance. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities. Actual results could differ from those projected in these forward-looking statements which are made as of the date of this presentation, and we assume no obligation to update any forward-looking statements. Our actual results may differ materially from those stated or implied in such forward-looking statements, due to risks and uncertainties associated with our business, which include the risk factors disclosed in our public filings.

Although we believe that any beliefs, plans, expectations and intentions contained in this presentation are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should review all of the information set forth herein, and should also understand the risk factors and the inherent uncertainties associated with new business opportunities and development stage. Any use of this information for any purpose other than in connection with the consideration of an investment in Q BioMed Inc. may subject the user to criminal and civil liability.

This presentation does not constitute an offer to sell any securities or the solicitation of an offer to sell any securities by Q BioMed Inc.
This is Our Growing Portfolio of High-Value Assets

<table>
<thead>
<tr>
<th>Oncology</th>
<th>Ophthalmology</th>
</tr>
</thead>
<tbody>
<tr>
<td>stromium\textsuperscript{89}</td>
<td>MAN-01</td>
</tr>
<tr>
<td>UTTROSIDE-B</td>
<td>MAN-11</td>
</tr>
<tr>
<td>Metastron</td>
<td>GDF15</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Rare/Orphan Disease</th>
<th>Vascular Disease</th>
</tr>
</thead>
<tbody>
<tr>
<td>\textbf{QB Med}-001</td>
<td>MAN-03</td>
</tr>
<tr>
<td>UTTROSIDE-B</td>
<td>MAN-04</td>
</tr>
</tbody>
</table>
# A Growing Pipeline Mitigates Risk and Drives Shareholder Value

<table>
<thead>
<tr>
<th>DRUG CANDIDATE</th>
<th>PRECLINICAL</th>
<th>PHASE 1</th>
<th>PHASE 2</th>
<th>PHASE 3</th>
<th>APPROVAL</th>
<th>COMMERCIALIZATION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Metaxtron strontium&lt;sup&gt;89&lt;/sup&gt;</td>
<td>Radiopharmaceutical for metastatic cancer bone pain</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>QBM-001</td>
<td>Pediatric non-verbal Autism Spectrum Disorder (Pre-IND 505b2)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>UTTROside-B</td>
<td>Chemotherapeutic for liver cancer</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAN 01</td>
<td>Topical eyedrops for glaucoma</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAN 02</td>
<td>Kidney Disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAN 03</td>
<td>Cardiovascular Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MAN 04</td>
<td>Infectious Diseases</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Corporate Introduction
Rapid biotech growth has created a plethora of scientific assets. And with so many assets being developed so quickly, things fall by the wayside... even if they shouldn’t.

That’s the cost of innovation.
At Q BioMed, we find undiscovered or undervalued biomedical technologies and maximize their potential yield.

That’s the opportunity
Our leading commercial asset is

strontium\textsuperscript{89}
Strontium Chloride Sr-89
Injection, USP

FDA Approved November 2019
Full Commercialization February/March 2020
Oncology Landscape
Current oncology landscape

- Science has extended life with cancer, but as a society we now need to address how we wish to experience the end of life.
- The end of life demands better, multimodal care that puts the patient and their desires first for a dignified and pain-free transition.
Bone metastases

- The skeleton is a potential metastatic target of many malignant tumors
  - Up to 85% of prostate and breast cancer patients may develop bone metastases
  - Data suggest that ~10 million people worldwide experience daily pain due to malignant disease; in half of these people, metastatic bone discomfort is the dominant source of symptoms\(^1\)
  - The prognosis of patients with metastases confined to the skeleton is usually superior to that of patients with soft-tissue metastases\(^2\)

- Widespread skeletal metastases is difficult to effectively treat with external beam radiation alone — the primary treatment modality

---

Mets lead to overwhelming bone pain

- The majority of patients with bone metastases develop severe pain as their disease progresses, resulting in a considerable reduction in their QoL
  - ~75% of patients with bone mets complain of pain as their main symptom and the dominant reason for a decreased QoL
  - Appropriate pain management may be difficult, particularly in the case of poorly localized discomfort

- A multidisciplinary approach to symptom palliation is recommended, tailoring treatment to individual need, with the aim of individualized treatment being “to add life to the years, not years to the life”

- Analgesic drugs, surgical interventions, local external-beam radiation therapy, and radiopharmaceutical therapies called ‘radionuclides’ have been developed and utilized for the systemic palliation of bone pain with more multilocular skeletal involvement

Worldwide market opportunity

10 Million
The number of people worldwide that experience daily pain due to malignant disease

75,000
The projected number of annual Sr-89 doses based on 0.5% of the market - 50,000 patients at 1.5 doses

8.4 Percent
The approximate CAGR at which the global bone metastasis market is expected to grow

2. Medgadget
About Strontium-89/METASTRON™
Sr-89 mechanism of action

- Sr-89 selectively targets and accumulates in metastatic bone lesions with minimal risk of toxicity to surrounding normal tissue.
- Sr-89 provides advantageous cross-fire destruction of targeted tumor cells.
- The long half-life of Sr-89 enables widespread incorporation into bone lesion surfaces and prolonged targeting of metastatic sites.
- The therapeutic range of Sr-89 within bone metastases helps provide comprehensive tumor targeting.
Efficacy of Sr-89 in the management of painful bone metastases

- Treatment with Sr-89 has led to a significant improvement in QoL for patients with metastatic bone disease associated with breast and prostate cancer
- Median duration of pain palliation with Sr-89 has been reported to span approximately 2-5 months
- Treatment with Sr-89 has been demonstrated to reduce or eliminate need for analgesics
- Addition of Sr-89 to other treatment modalities, including chemotherapy and EBRT, has been demonstrated to augment therapeutic efficacy

“"I thought [Strontium] was the coolest thing. Great responses. The pain dramatically improved in the breast patients that had bone metastases.”*

- Radiation Oncologist

*Source: Q BioMed Qual Market Research; July 2018
**METASTRON™ effectively palliates cancer bone pain**

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients (N)</th>
<th>Dose</th>
<th>Cancer</th>
<th>Pain Relief</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fuster 2000</td>
<td>40</td>
<td>4 mCi</td>
<td>Breast</td>
<td>92%</td>
</tr>
<tr>
<td>Kraeber-Bodere 2000</td>
<td>94</td>
<td>4 mCi</td>
<td>Prostate</td>
<td>78%</td>
</tr>
<tr>
<td>Turner 2001</td>
<td>93</td>
<td>4 mCi</td>
<td>Prostate</td>
<td>63%</td>
</tr>
<tr>
<td>Ashayeri 2002</td>
<td>27</td>
<td>4 mCi</td>
<td>Prostate and Breast</td>
<td>81%</td>
</tr>
<tr>
<td>Gunawardana 2004</td>
<td>13</td>
<td>4 mCi</td>
<td>Prostate</td>
<td>57%</td>
</tr>
<tr>
<td>Liepe 2007</td>
<td>15</td>
<td>4 mCi</td>
<td>Prostate and Breast</td>
<td>72%</td>
</tr>
</tbody>
</table>
**METASTRON™ offers lasting pain relief**

<table>
<thead>
<tr>
<th>Study</th>
<th>Patients (N)</th>
<th>Dose</th>
<th>Cancer</th>
<th>Pain Relief</th>
<th>Median duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fuster 2000</td>
<td>40</td>
<td>4 mCi</td>
<td>Breast</td>
<td>92%</td>
<td>120 days</td>
</tr>
<tr>
<td>Kraeber-Bodere 2000</td>
<td>94</td>
<td>4 mCi</td>
<td>Prostate</td>
<td>78%</td>
<td>Moderate bone involvement: 5 mos</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Extensive bone involvement: 2 mos</td>
</tr>
<tr>
<td>Gunawardana 2004</td>
<td>13</td>
<td>4 mCi</td>
<td>Prostate</td>
<td>57%</td>
<td>56 days</td>
</tr>
</tbody>
</table>
Potential for therapeutic indication

- A decrease of >50% in serum PSAV was observed in 37% of patients with hormone-refractory prostate cancer after treatment with METASTRON™

- In a multicenter, RCT involving 126 patients with mCRPC, all of whom received external beam radiotherapy, additional treatment with METASTRON™ delayed disease progression [Porter_1993]

- Many patients show a reduced intensity of hot spots on bone scan compared with pretreatment images, suggesting a possible tumoricidal effect from METASTRON™

- Case reports describe regression of osteoblastic and osteolytic bone metastases in patients with breast cancer and hepatocellular carcinoma after treatment with METASTRON™

- In the recent TRAPEZE randomized controlled trial of the clinical effectiveness and cost-effectiveness of chemotherapy with zoledronic acid (ZA), METASTRON, or both in men with bony metastatic castration-refractory prostate cancer, METASTRON was shown to improve CPFS, while ZA did not

A potential survival benefit associated with the use of Sr-89 has been reported, and future randomized, placebo-controlled studies may confirm the effect of Sr-89 on overall survival
Increasing evidence of an overall survival benefit with METASTRON™

- In one study of 103 patients with mCRPC randomized to doxorubicin alone or doxorubicin with METASTRON, a median overall survival of 16.8 months and 27.7 months was seen, respectively\(^9\)

- In an earlier trial examining METASTRON vs placebo in mPC and mCPRC patients, Buchali et al reported a survival rate 2 years after the start of treatment of 46% in METASTRON and 4% in placebo groups\(^19\)

- In these clinical studies, differences in METASTRON dosing, baseline patient characteristics, and prior treatments are likely to affect reported outcomes

Future randomized, placebo-controlled studies may confirm the effect of Sr-89 on overall survival
METASTRON™ / Strontium-89: summary

Today:
• FDA approved for pain palliation
• NDA and ANDA held by Q BioMed
  • Operationalizing radiopharmaceuticals is highly complex, creating a high barrier to generic entry
• Global market authorizations held for METASTRON in 22 countries
• Medicare/payor reimbursed
• Slated to be commercially available in Feb/March 2020
  (US FDA manufacturing facility approval - Nov 2019)

In the future:
• Phase 4 clinical program planned to expand label to include overall survival (OS)
The METASTRON™ U.S. commercial plan is in place...
MAN-01 Topical Drops
Primary Open-Angle Glaucoma
60 million patients worldwide
Mannin RESEARCH

Pharmaceutical:
MAN-01

Condition:
Primary Open-Angle Glaucoma

Addressable Market:
60 million patients worldwide

Technology Partner:
Mannin RESEARCH

Stage:
Preclinical

Portfolio Biotechnology
THE CONDITION:

Intraocular Pressure (IOP) and Primary Open-Angle Glaucoma

Prevalence

60 million glaucoma patients worldwide

8 million with bilateral blindness

Typically no early warning signs. Therapy only slows progression

Current Standards of Care

Medical (Pharmaceuticals)
Laser Surgery (Out-patient)
Traditional Surgery (In-patient)

Market Is Seeking

Effective reduction in IOP
Innovative Drug Design
Increase compliance and adherence
Improved drug delivery and availability
First-in-class drug to treat Glaucoma

Novel therapeutic addresses need for innovation

Mechanism targets the critical Schlemm’s Canal
  The Schlemms Canal is responsible for 70%-90% of fluid drainage in the eye

Primary indication for Primary Open-Angle Glaucoma
  Additional indications may include:
  - Acute Kidney Injury
  - Cardiovascular Disease
  - Infectious Diseases

Mannin Research accepted into Johnson & Johnson Innovation, JLABS @ Toronto
  Developing a novel eye-drop to treat Primary Open-Angle Glaucoma utilizing the Angiopoietin-Tie2 Mechanism of Action

Glaucoma Cases Expected to Increase 30% by 2020
(millions of cases)

Source: W.H.O. 2010

Projected Phase I Glaucoma Clinical Trial:
Q1 2021

Projected Lead Candidate Selection:
Q3 2020
Additional Indications: Pre-Clinical

**MAN 02** Acute Kidney Injury

Treatment for Acute Kidney Injury, which contributes to high morbidity and mortality rate in a wide range of injuries, including common clinical care settings such as coronary artery bypass surgery, contrast-induced nephropathy and sickle cell nephropathy.

**MAN 03** Cardiovascular Diseases

Treatment with our pharmacologic small molecule will likely protect the lungs and slow disease progression in patients with Pulmonary Artery Hypertension. Treatment may also provide protection to the myocardium in patients with Congestive Heart Failure and Myocardial Ischemia.

**MAN 04** Infectious Diseases

Interventions targeting Ang-Tie2 pathway have been shown to play an important role in reducing the severity of viral and bacterial infections such as influenza, sepsis, tuberculosis, anthrax, toxic shock syndrome, cerebral malaria and Ebola, by promoting positive host-directed therapeutic (HDT) responses.
<table>
<thead>
<tr>
<th>Biomarker &amp; Companion Diagnostic</th>
<th>GDF15</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Condition:</strong></td>
<td>Monitoring Glaucomatous Neurodegeneration</td>
</tr>
<tr>
<td>Addressable Market:</td>
<td>60 million</td>
</tr>
<tr>
<td>Technology Partner:</td>
<td>Washington University in St. Louis</td>
</tr>
<tr>
<td><strong>Stage:</strong></td>
<td>Preclinical Development of Diagnostic Kit; Clinical Trials using GDF15 as biomarker</td>
</tr>
</tbody>
</table>
GDF-15: Novel Biomarker for Glaucoma

- Growth Differentiation Factor 15 (GDF15) is a member of the transforming growth factor (TGF-β) superfamily and was recently identified as a promising biomarker for glaucoma.
- Validated in both rat models of glaucoma and human patients and its expression correlated with disease severity.
- GDF15 represents an attractive biomarker for glaucoma with distinct advantages (i.e., early detection) over conventional clinical tests and has the potential to be a first-in-class diagnostic test.
- Provides a unique product offering in a huge market
- Companion diagnostic to Man01
- Diagnostic test for all patients
- Surrogate end-point test for Glaucoma trials (Pharma)

*Patent Application: 62/289,030*
Monitoring Glaucomatous Neurodegeneration

- Accurate monitoring for evidence of disease progression is vital to preserve visual function of glaucoma patients
- Desired goal of any glaucoma therapeutic intervention is neuroprotection, leading to survival of retinal ganglion cells (RGCs)
- Physicians currently have only surrogate measures of glaucomatous neurodegeneration
- No single examination or diagnostic test is able to accurately predict disease progression

<table>
<thead>
<tr>
<th>Tonometry (IOP measurement)</th>
<th>Optical Coherence Tomography (OCT)</th>
<th>Examination of the Optic Nerve</th>
<th>Perimetry (Visual Field Testing)</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pros:</strong></td>
<td><strong>Pros:</strong></td>
<td><strong>Pros:</strong></td>
<td><strong>Pros:</strong></td>
</tr>
<tr>
<td>• Essential for assessing the effectiveness of IOP lowering treatment</td>
<td>• Automated</td>
<td>• Can be performed routinely in a clinical seeing</td>
<td>• Direct measurement of glaucoma in the patient’s visual function</td>
</tr>
<tr>
<td>• No direct correlation with glaucomatous neurodegeneration</td>
<td>• Objectively quantifiable</td>
<td>• Can be recorded by a photograph</td>
<td></td>
</tr>
<tr>
<td><strong>Cons:</strong></td>
<td><strong>Cons:</strong></td>
<td><strong>Cons:</strong></td>
<td><strong>Cons:</strong></td>
</tr>
<tr>
<td>• Values are affected by central corneal thickness</td>
<td>• No reliable normative database</td>
<td>• Subjective (observer designates the rim margin of the cup)</td>
<td>• Subjective (patients respond when the light is projected)</td>
</tr>
</tbody>
</table>
UTTROSIDE-B

Chemotherapy: UTTROCIDE-B
Condition: Liver Cancer
Addressable Market: 700,000 diagnoses/year
Technology Partner: Oklahoma Medical Research Foundation
Stage: Preclinical
More than 700,000 people worldwide are diagnosed each year. Estimated 39,230 adults in the United States will be diagnosed every year. Numbers have tripled since 1980.

Prevalence

Poor 1-year survival rate
18% 5yr Survival

Current Standards of Care

**RADIATION**
High-energy x-rays or other particles destroy cancer cells

**DRUG TREATMENT**
Tryosine kinase inhibitor antineoplastic agent, Nexavar™

**SURGICAL**
Hepatectomy or liver transplantation

**CHEMOTHERAPY**
Radiofrequency ablation (RFA) and microwave therapy

**THERMAL**
Percutaneous ethanol injection
P Uttroside-B appears to affect phosphorylated JNK (pro survival signaling) and caspase activity (apoptosis in liver cancer)

- A natural compound
- Fractionated Saponin derived from S. nigrum
- Small molecule
- Steroid Glycoside

Uttroside B increases the cytotoxicity of a variety of liver cancer cell types

- Up to 10x more potent than Sorafenib in preclinical studies

Cytotoxicity specific to cancerous liver cells

Provisional patent filed

Molecule syntheses completion Aug 2019

IND Ready Q4 2020

Sorafenib Tosylate (Nexavar™) is currently the only FDA- approved drug for the first line treatment of liver cancer. 2017 sales exceed $1B
Pharmaceutical: QBM-001 sprinkle formulation
Condition: Rare Pediatric Non-Verbal Disorder
Addressable Market: 50,000 cases worldwide
15,000 in US alone
Stage: Pre-IND 505(b)2
About 20,000 children will be diagnosed with pediatric minimally verbal autism each year in the US alone. They will have to rely on assisted living for the rest of their life. Of the estimated 20,000, QBM-001 should be able to treat about 15,000. There is estimated to be over 250,000 children globally with pediatric minimally verbal autism.

- The lifetime cost of care is estimated at $5-10 M/person in the US.
- No treatment with lasting effects on how children develop
- Fundamental defects in social reciprocity and communication
- Repetitive and stereotypical behaviors

**Current *Medications and 2016 Sales**

<table>
<thead>
<tr>
<th>Name</th>
<th>Condition</th>
<th>2016 Sales</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abilify®</td>
<td>Irritability</td>
<td>$2.0 B + (off Patent)</td>
</tr>
<tr>
<td>Vyvanse®</td>
<td>ADHD</td>
<td>$2.0 B</td>
</tr>
<tr>
<td>Risperdal®</td>
<td>Aggression</td>
<td>$3.0 B</td>
</tr>
</tbody>
</table>

*These medications do not treat the condition, rather they are psychotherapeutic interventions that ameliorate temperament/mood only.
Synapse Formation

- **8-12 months** - detection of early symptoms
- **12-15 months** - language regression or the child never progresses with language
- Brain density in cortex (speech region) declines after 24 months

Multiple studies confirm a loss in density of neurons in the cortex region in children with pediatric minimally verbal autism compared to other autistic children and healthy controls by age 7.

**HOW IT WORKS**

**Diagnosis**
- Differential diagnosis as early as 3.5 years of age
- Tested for elevated serum and biomarkers markers
- Genetically tested to exclude diseases that QBM-001 cannot treat

QBM-001 targets multiple pathways that are faulty in these children. It ameliorates negative feedback loops in the body of these children that prevents them from being able to develop language.

Biomarker Diagnosis - Q BioMed has also identified two unique miRNA biomarkers for this subset and is planning the next steps to validate these biomarkers. This would allow us to diagnose and treat as young as 2 years of age.

**QBM-001**

Regulates Faulty Pathways to Allow Language Development

- **8-12 months** - detection of early symptoms
- **12-15 months** - language regression or the child never progresses with language
- **Brain density in cortex (speech region) declines after 24 months**

**NEURON PRUNING**

Children with ASD lose the ability to learn language once their language-specific neurons are naturally pruned.

At 2 years of age, the brain is actively developing neuron connections at the peak of the leaning process.

Around the age 2, the brain more actively prunes (eliminates) neurons that are not in use.

When language development is impeded in this subset of ASD children, their language neurons do not activate and are targeted for pruning by the brain.

If you do not use it, you lose it.
There are NO drugs currently available to ameliorate this condition.

Orphan drugs (less than 200k patients) average price $100,000 per year (EvaluatePharma).

The alternative - estimated at $5m in direct costs and up to $5M in lost productivity due to lifetime assisted living, supplemental healthcare costs, and lost productivity of family members.

Not measuring the severe emotional strain of never talking to your child.

Pediatric minimally verbal autism, where children lose or don’t develop and manifest with ASD symptoms is rare and limited to approximately 250,000 children worldwide. 20,000 children a year in the US alone.

MARKET POTENTIAL
United States alone: 20,000 patients per year @ $100,000 - $2B
Capital Markets Overview and Management Outlook
# Capital Markets

As of Dec 4, 2018

<table>
<thead>
<tr>
<th>Shares Outstanding</th>
<th>20,200,000</th>
<th>Market Cap</th>
<th>$50M</th>
</tr>
</thead>
<tbody>
<tr>
<td>Warrants</td>
<td>8.8M</td>
<td>Ave Price</td>
<td>$3.50</td>
</tr>
<tr>
<td>Inside Ownership</td>
<td>25%</td>
<td>Avg. Volume</td>
<td>100,000</td>
</tr>
<tr>
<td>Float</td>
<td>~ 13,000,000</td>
<td>Year end</td>
<td>November 30</td>
</tr>
</tbody>
</table>

**3-Month Trading History**

**Price $3.00**

[Graph showing trading history with price data from 12/04/10]
What to expect from us

Sales LAUNCH - Revenue generation expected in Q2 2020
Ph4 Post Marketing Study SAB for Expanded Therapeutic Label Q4 20
Revenue in 2020

QBM-001
Pre-IND Filing, Q4 2020
1.5year Pivotal Clinical Trial Initiation Q2 2021 (505b2)

Uttroside-B - Liver Cancer
Complete pre-clinical and Prepare IND Q4 2020
Proof of Concept Studies H2 2021

MAN-01
Complete Molecule Optimization (Eye Drop)
Initiate Pre-IND Studies 2H2020 - Clinical Trial IND Q42020 - Clin Trial 2021
Additional Indications Formalized 2019/2020
Pharma Partnership opportunities

Potential up-list to national exchange in H2 2020
Management Team
Management Team

Denis Corin
Chief Executive Officer
Chairman of the Board

William Rosenstadt
Chief Legal Officer
General Counsel
Director

Dr. Rick Panicucci
Pharmaceutical Development Director

Ari Jatwes
Business Development Analyst

David Laskow-Pooley
VP Product Development

Robert Derham
VP Orphan Products

Advisory Board

Dr. Helen Tager-Flusberg
Professor of Psychology
Director of the Center for Autism Research Excellence
Boston University

George Nikopoulos
CEO, Mannin Research

Dr. Susan Quaggin
CSO, Mannin Research
Director, Feinberg Cardiovascular and Renal Research Institute
Chief of Nephrology and HTN in the Department of Medicine

Dr. Charles H. Mayo
Professor of Medicine (Nephrology and Hypertension)
Northwestern University

Dr. Amy Ripka
Medicinal Chemistry
BioChemistry and Molecular Genetics
NIH Post Doc fellow

Kristin Keller
Commercialization Lead
Marketing and commercialization

Dr. Raj Apte
Washington University - Ophthalmology
Paul A. Cibis Distinguished Professor of Ophthalmology and Visual Sciences

Dr. John Jay Gargus
Professor, Physiology & Biophysics
Director of Center for Autism Research and Translation (UCI CART)
Professor, Pediatrics, UC Irvine School of Medicine

Dr. Jin Jeng
Recombinant Protein
Ophthalmology
Northwestern Feinberg School of Medicine
Assistant Professor of Medicine (Nephrology and Hypertension)